- Home
- FRES vs LGVN Comparison
FRES vs LGVN Comparison
Compare FRES & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRES
- LGVN
- Stock Information
- Founded
- FRES 2010
- LGVN 2014
- Country
- FRES United States
- LGVN United States
- Employees
- FRES N/A
- LGVN N/A
- Industry
- FRES Medical Specialities
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- FRES Health Care
- LGVN Health Care
- Exchange
- FRES Nasdaq
- LGVN Nasdaq
- Market Cap
- FRES N/A
- LGVN 25.9M
- IPO Year
- FRES 2020
- LGVN 2021
- Fundamental
- Price
- FRES $1.66
- LGVN $2.09
- Analyst Decision
- FRES
- LGVN Strong Buy
- Analyst Count
- FRES 0
- LGVN 2
- Target Price
- FRES N/A
- LGVN $8.00
- AVG Volume (30 Days)
- FRES 32.8K
- LGVN 393.6K
- Earning Date
- FRES 10-29-2024
- LGVN 11-08-2024
- Dividend Yield
- FRES N/A
- LGVN N/A
- EPS Growth
- FRES N/A
- LGVN N/A
- EPS
- FRES N/A
- LGVN N/A
- Revenue
- FRES $2,341,326.00
- LGVN $1,229,000.00
- Revenue This Year
- FRES N/A
- LGVN $161.78
- Revenue Next Year
- FRES N/A
- LGVN $8.62
- P/E Ratio
- FRES N/A
- LGVN N/A
- Revenue Growth
- FRES 94.50
- LGVN 39.34
- 52 Week Low
- FRES $1.11
- LGVN $0.77
- 52 Week High
- FRES $18.00
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- FRES 51.75
- LGVN 54.70
- Support Level
- FRES $1.51
- LGVN $1.76
- Resistance Level
- FRES $2.36
- LGVN $2.26
- Average True Range (ATR)
- FRES 0.19
- LGVN 0.12
- MACD
- FRES 0.06
- LGVN 0.05
- Stochastic Oscillator
- FRES 38.60
- LGVN 66.00
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.